Microglia, amyloid, and glucose metabolism in parkinson's disease with and without dementia

Neuropsychopharmacology

Volumn 38, Issue 6, 2013, Pages 938-949

  Edison, Paul ^a   Ahmed, Imtiaz ^a,c   Fan, Zhen ^a   Hinz, Rainer ^a,b   Gelosa, Giorgio ^a,c   Ray Chaudhuri, K ^d   Walker, Zuzana ^e   Turkheimer, Federico E ^a,d   Brooks, David J ^a,f  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c UNIVERSITY OF MILANO BICOCCA   (Italy)

^d KING'S COLLEGE LONDON   (United Kingdom)

^e UNIVERSITY COLLEGE LONDON   (United Kingdom)

^f GE HEALTHCARE   (United Kingdom)

Author keywords

amyloid; glucose metabolism; microglia; Parkinson's disease; Parkinson's disease dementia

Indexed keywords

AMYLOID; CARBON 11; FLUORODEOXYGLUCOSE F 18; GLUCOSE; N SEC BUTYL 1 (2 CHLOROPHENYL) N METHYL 3 ISOQUINOLINECARBOXAMIDE;

ANTERIOR CINGULATE; ARTICLE; BRAIN MAPPING; CELL ACTIVATION; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; CORPUS STRIATUM; DEMENTIA; DRUG UPTAKE; FRONTAL CORTEX; GLUCOSE METABOLISM; HUMAN; MICROGLIA; MINI MENTAL STATE EXAMINATION; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; OCCIPITAL CORTEX; PARIETAL CORTEX; PARKINSON DISEASE; PET SCANNER; POSITRON EMISSION TOMOGRAPHY; POSTERIOR CINGULATE; PRIORITY JOURNAL; TEMPORAL CORTEX;

AGED; AGED, 80 AND OVER; AMYLOID; COHORT STUDIES; DEMENTIA; FEMALE; GLUCOSE; HUMANS; MALE; MICROGLIA; MIDDLE AGED; PARKINSON DISEASE; POSITRON-EMISSION TOMOGRAPHY;

EID: 84878564712     PISSN: 0893133X     EISSN: 1740634X     Source Type: Journal    
DOI: 10.1038/npp.2012.255     Document Type: Article

References (46)

1. Anderson AN, Pavese N, Edison P, Tai YF, Hammers A, Gerhard A et al (2007). A systematic comparison of kinetic modelling methods generating parametric maps for [(11)C]-(R)-PK11195. Neuroimage 36: 28-37.
2. Banati RB, Newcombe J, Gunn RN, Cagnin A, Turkheimer F, Heppner F et al (2000). The peripheral benzodiazepine binding site in the brain in multiple sclerosis: quantitative in vivo imaging of microglia as a measure of disease activity. Brain 123 (Pt 11) 2321-2337.
3. Berding G, Odin P, Brooks DJ, Nikkhah G, Matthies C, Peschel T et al (2001). Resting regional cerebral glucose metabolism in advanced Parkinson's disease studied in the off and on conditions with [(18)F]FDG-PET. Mov Disord 16: 1014-1022.
4. Borghammer P, Chakravarty M, Jonsdottir KY, Sato N, Matsuda H, Ito K et al (2010). Cortical hypometabolism and hypoperfusion in Parkinson's disease is extensive: probably even at early disease stages. Brain Struct Funct 214: 303-317.
5. Borghammer P, Cumming P, Aanerud J, Forster S, Gjedde A (2009). Subcortical elevation of metabolism in Parkinson's disease-a critical reappraisal in the context of global mean normalization. Neuroimage 47: 1514-1521.
6. Brix G, Zaers J, Adam LE, Bellemann ME, Ostertag H, Trojan H et al (1997). Performance evaluation of a whole-body PET scanner using the NEMA protocol. National Electrical Manufacturers Association. J Nucl Med 38: 1614-1623.
7. Cummings JL (1988). Intellectual impairment in Parkinson's disease: clinical, pathologic, and biochemical correlates. J Geriatr Psychiatry Neurol 1: 24-36.
8. Cunningham VJ, Jones T (1993). Spectral analysis of dynamic PET studies. J Cereb Blood Flow Metab 13: 15-23.
9. Eberling JL, Richardson BC, Reed BR, Wolfe N, Jagust WJ (1994). Cortical glucose metabolism in Parkinson's disease without dementia. Neurobiol Aging 15: 329-335.
10. Edison P, Archer HA, Gerhard A, Hinz R, Pavese N, Turkheimer FE et al (2008a). Microglia, amyloid, and cognition in Alzheimer's disease: An [11C](R)PK11195-PET and [11C]PIBPET study. Neurobiol Dis 32: 412-419.
11. Edison P, Archer HA, Hinz R, Hammers A, Pavese N, Tai YF et al (2007). Amyloid, hypometabolism, and cognition in Alzheimer disease: an [11C]PIB and [18F]FDG PET study. Neurology 68: 501-508.
12. Edison P, Rowe CC, Rinne JO, Ng S, Ahmed I, Kemppainen N et al (2008b). Amyloid load in Parkinson's disease dementia and Lewy body dementia measured with [11C]PIB positron emission tomography. J Neurol Neurosurg Psychiatry 79: 1331-1338.
13. Emre M, Aarsland D, Brown R, Burn DJ, Duyckaerts C, Mizuno Y et al (2007). Clinical diagnostic criteria for dementia associated with Parkinson's disease. Mov Disord 22: 1689-1707.
14. Feng T, Wang Y, Ouyang Q, Duan Z, Li W, Lu L et al (2008). Comparison of cerebral glucose metabolism between multiple system atrophy Parkinsonian type and Parkinson's disease. Neurol Res 30: 377-382.
15. Gerhard A, Pavese N, Hotton G, Turkheimer F, Es M, Hammers A et al (2006). In vivo imaging of microglial activation with [11C](R)-PK11195 PET in idiopathic Parkinson's disease. Neurobiol Dis 21: 404-412.
16. Gomperts SN, Rentz DM, Moran E, Becker JA, Locascio JJ, Klunk WE et al (2008). Imaging amyloid deposition in Lewy body diseases. Neurology 71: 903-910.
17. Hammers A, Allom R, Koepp MJ, Free SL, Myers R, Lemieux L et al (2003). Three-dimensional maximum probability atlas of the human brain, with particular reference to the temporal lobe. Hum Brain Mapp 19: 224-247.
18. Hirsch EC, Breidert T, Rousselet E, Hunot S, Hartmann A, Michel PP (2003). The role of glial reaction and inflammation in Parkinson's disease. Ann NY Acad Sci 991: 214-228.
19. Hosokai Y, Nishio Y, Hirayama K, Takeda A, Ishioka T, Sawada Y et al (2009). Distinct patterns of regional cerebral glucose metabolism in Parkinson's disease with and without mild cognitive impairment. Mov Disord 24: 854-862.
20. Hu MT, Taylor-Robinson SD, Chaudhuri KR, Bell JD, Labbe C, Cunningham VJ et al (2000). Cortical dysfunction in nondemented Parkinson's disease patients: a combined (31)P-MRS and (18)FDG-PET study. Brain 123, Pt 2 340-352.
21. Hughes TA, Ross HF, Musa S, Bhattacherjee S, Nathan RN, Mindham RH et al (2000). A 10-year study of the incidence of and factors predicting dementia in Parkinson's disease. Neurology 54: 1596-1602.
22. Iannaccone S, Cerami C, Alessio M, Garibotto V, Panzacchi A, Olivieri S et al (2012). In vivo microglia activation in very early dementia with Lewy bodies, comparison with Parkinson's disease. Parkinsonism Relat Disord (in press) doi:10.1016/j.parkreldis. 2012.07.002
23. Jellinger KA, Attems J (2006). Does striatal pathology distinguish Parkinson disease with dementia and dementia with Lewy bodies? Acta Neuropathol 112: 253-260.
24. Klein JC, Eggers C, Kalbe E, Weisenbach S, Hohmann C, Vollmar S et al (2010). Neurotransmitter changes in dementia with Lewy bodies and Parkinson disease dementia in vivo. Neurology 74: 885-892.
25. Klunk WE (2011). Amyloid imaging as a biomarker for cerebral beta-amyloidosis and risk prediction for Alzheimer dementia. Neurobiol Aging 32(Suppl 1): S20-S36
26. Klunk WE, Wang Y, Huang GF, Debnath ML, Holt DP, Shao L et al (2003). The binding of 2-(40-methylaminophenyl)benzothiazole to postmortem brain homogenates is dominated by the amyloid component. J Neurosci 23: 2086-2092.
27. Liang T-W, Noorigian JV, Duda. JE (2006). Does striatal pathology distinguish PDD from DLB? Mov Disord 21(Suppl 13): S69
28. Lopresti BJ, Klunk WE, Mathis CA, Hoge JA, Ziolko SK, Lu X et al (2005). Simplified Quantification of Pittsburgh Compound B Amyloid Imaging PET Studies: a comparative analysis. J Nucl Med 46: 1959-1972.
29. Maetzler W, Liepelt I, Reimold M, Reischl G, Solbach C, Becker C et al (2009). Cortical PIB binding in Lewy body disease is associated with Alzheimer-like characteristics. Neurobiol Dis 34: 107-112.
30. Maetzler W, Reimold M, Liepelt I, Solbach C, Leyhe T, Schweitzer K et al (2008). [11C]PIB binding in Parkinson's disease dementia. Neuroimage 39: 1027-1033.
31. McGeer PL, McGeer EG (2004). Inflammation and the degenerative diseases of aging. Ann N Y Acad Sci 1035: 104-116.
32. McGeer PL, Schwab C, Parent A, Doudet D (2003). Presence of reactive microglia in monkey substantia nigra years after 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine administration. Ann Neurol 54: 599-604.
33. Nordberg A, Rinne JO, Kadir A, Langstrom B (2010). The use of PET in Alzheimer disease. Nat Rev Neurol 6: 78-87.
34. Peppard RF, Martin WR, Carr GD, Grochowski E, Schulzer M, Guttman M et al (1992). Cerebral glucose metabolism in Parkinson's disease with and without dementia. Arch Neurol 49: 1262-1268.
35. Peppard RF, Martin WR, Clark CM, Carr GD, McGeer PL, Calne DB (1990). Cortical glucose metabolism in Parkinson's and Alzheimer's disease. J Neurosci Res 27: 561-568.
36. Pike KE, Savage G, Villemagne VL, Ng S, Moss SA, Maruff P et al (2007). {Beta}-amyloid imaging and memory in non-demented individuals evidence for preclinical Alzheimer's disease. Brain 130, Pt 11 2837-2844.
37. Rowe CC, Ellis KA, Rimajova M, Bourgeat P, Pike KE, Jones G et al (2010). Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging. Neurobiol Aging 31: 1275-1283.
38. Sasaki M, Ichiya Y, Hosokawa S, Otsuka M, Kuwabara Y, Fukumura T et al (1992). Regional cerebral glucose metabolism in patients with Parkinson's disease with or without dementia. Ann Nucl Med 6: 241-246.
39. Shah F, Hume SP, Pike VW, Ashworth S, McDermott J (1994). Synthesis of the enantiomers of [N-methyl-11C]PK 11195 and comparison of their behaviours as radioligands for PK binding sites in rats. Nucl Med Biol 21: 573-581.
40. Spinks TJ, Jones T, Bloomfield PM, Bailey DL, Miller M, Hogg D et al (2000). Physical characteristics of the ECAT EXACT3D positron tomograph. Phys Med Biol 45: 2601-2618.
41. Turkheimer FE, Edison P, Pavese N, Roncaroli F, Anderson AN, Hammers A et al (2007). Reference and target region modeling of [11C]-(R)-PK11195 brain studies. J Nucl Med 48: 158-167.
42. Vander Borght T, Minoshima S, Giordani B, Foster NL, Frey KA, Berent S et al (1997). Cerebral metabolic differences in Parkinson's and Alzheimer's diseases matched for dementia severity. J Nucl Med 38: 797-802.
43. Weiner MW, Veitch DP, Aisen PS, Beckett LA, Cairns NJ, Green RC et al (2012). The Alzheimer's Disease Neuroimaging Initiative: a review of papers published since its inception. Alzheimers Dement 8(1 Suppl): S1-S68
44. Wyss-Coray T, Mucke L (2002). Inflammation in neurodegenerative disease-a double-edged sword. Neuron 35: 419-432.
45. Yong SW, Yoon JK, An YS, Lee PH (2007). A comparison of cerebral glucose metabolism in Parkinson's disease, Parkinson's disease dementia and dementia with Lewy bodies. Eur J Neurol 14: 1357-1362.
46. Zhang W, Wang T, Pei Z, Miller DS, Wu X, Block ML et al (2005). Aggregated alpha-synuclein activates microglia: a process leading to disease progression in Parkinson's disease. Faseb J 19: 533-542